Medical AI company Lunit (CEO Bumseok Seo) announced on the 21st that its subsidiary Volpara Health, acquired in May, has signed a breast cancer screening software supply contract with Intermountain Health, one of the largest healthcare systems in the United States.
The supplied products include Volpara's flagship software Risk Pathway, Analytics, and Scorecard. These products will be used for cancer risk assessment, breast tissue density evaluation, and mammography quality improvement at Intermountain Health.
Intermountain Health is the largest nonprofit healthcare system in the western United States, operating 34 hospitals and over 400 clinics across seven states including Utah, Idaho, and Nevada. It is the largest private employer in Utah with 58,000 employees. It is also recognized as a leader in the adoption of medical AI in the U.S. Notably, last month, the global research firm CB Insights ranked Intermountain Health second in the Hospital AI Readiness Index, just behind the Mayo Clinic, one of the world’s top medical institutions.
Through this supply contract, Volpara is expected to further strengthen its position in the U.S. market by adding a major U.S. healthcare system to its new customer portfolio.
Terry Thomas, CEO of Volpara, said, “The contract with Intermountain Health reaffirms Volpara’s technological capabilities and presence in the U.S. market. Going forward, through synergy with Lunit, we will enhance our products and develop new solutions to provide optimized solutions to healthcare institutions with diverse needs.” Bumseok Seo, CEO of Lunit, also stated, “This contract is not only the first major achievement after Lunit’s acquisition of Volpara but also significant because it is with Intermountain Health, a leader in AI innovation. By combining the technological capabilities and networks of both Lunit and Volpara, we will further strengthen our competitiveness in the U.S. medical AI market.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
